Verismo Therapeutics

Lyell Immunopharma

This biopharmaceutical company develops chimeric antigen receptor T-cell therapies to treat patients with hematologic malignancies and solid tumours.

CARGO Therapeutics

This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.

Vivere Oncotherapies

This company develops engineered cancer immunotherapies to help the immune systems of patients with solid tumours detect and destroy malignant cells.

Leucid Bio

This biotechnology company develops chimeric antigen receptor T-cell therapies to treat patients with solid tumours and haematological malignancies.

CTRL Therapeutics

This company develops cell therapies for solid tumours and microfluidic platforms to identify rare tumour-reactive lymphocytes for cancer patients.

Alyssum Therapeutics

This company develops B cell-based targeted immunotherapies for patients with solid tumours and complex immunological conditions.

Carisma Theraputics

The company develops engineered macrophage and monocyte cell therapies for patients with solid tumours, liver fibrosis and other serious diseases.

CARISMA Therapeutics

This company develops engineered macrophage and monocyte cell therapies to treat patients with solid tumours and liver fibrosis.